ALE.P03

· Alentis Therapeutics AG

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for ALE.P03, covering 2026-03-19 to 2026-03-19. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors [Phase 1, Phase 2]

See pricing